The research was in collaboration with the Samsung Medical Center, Sungkyunkwan University School of Medicine. This study adds to the previous studies of p...
After helping to develop and test new mRNA technologies for COVID-19 vaccines, University of Maryland School of Medicine (UMSOM) researchers and scientists...
Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, announced a s...
The U.S. Department of Health and Human Services plans to end the federal COVID-19 Public Health Emergency on May 11, but ensuring access to novel vac...
RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of inn...
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the de...
One promising approach involves delivering antiviral compounds vaginally, using inserts, gels, films, or intravaginal rings. This method is appealing becau...
Xylyx Bio, a regenerative medicine company developing breakthrough technologies for organ and tissue repair, today announced findings from an independent c...
J-Brain Cargo®, which is a JCR proprietary technology, allows the delivery of biotherapeutics into the central nervous system (“CNS”) via a...
Histogen Inc. (HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-casp...
In the feasibility study, scientists at the Milan site will focus on identifying proof of concept and viability for developing a prototype for an exosome-b...
The funds will be mainly used to develop lead program Levodopa Cyclops™ for US and EEA marketing, of which early clinical studies already demonstrate...
“We are excited to begin working with Moderna on a specific application of our AI-enabled cryo-EM platform that leverages our technology infrastructu...
Under the terms of the agreement, Xeris will use its proprietary drug-formulation platform, XeriJect™, to develop ultra-highly concentrated, ready-to...
© 2026 Biopharma Boardroom. All Rights Reserved.
